AZN 241129 65.00C (AZN241129C65000) Stock Options, News & Quotes

US OptionsDetailed Quotes

AZN241129C65000

Watchlist

1.12
+0.70+166.67%

15min DelayClose Nov 22 15:59 ET

1.70High1.12Low

Intraday

5D
Daily

News

AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
MT Newswires57minutes ago
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
Yahoo FinanceNov 23 10:23 ET
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Seeking AlphaNov 23 08:26 ET
Trump Nominates Marty Makary For FDA Commissioner
Barron'sNov 22 22:27 ET
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Seeking AlphaNov 22 21:25 ET
Top Gap Ups and Downs on Friday: AZN, BABA, PDD and More
Moomoo NewsNov 22 18:00 ET · Markets

Comments

Phil Dunn

Nov 23 05:10

Portfolio Quick Update (3rd week Nov)

A quick update of my trading activities in this week (18 to 22 Nov).
New Positions
$Taiwan Semiconductor (TSM.US)$ , $Broadcom (AVGO.US)$ , $Johnson & Johnson (JNJ.US)$ , $Pfizer (PFE.US)$ , $Coca-Cola (KO.US)$ , $Occidental Petroleum (OXY.US)$
Sold out Positions
$Disney (DIS.US)$
Increased Positions
$Novo-Nordisk A/S (NVO.US)$ , $AstraZeneca (AZN.US)$ , $Huntington Ingalls Industries (HII.US)$
Decreased Positions
None

Trump trade: Bitcoin hit record highs and Tesla hits $1 trillion market cap

Movers and Shakers

Nov 20 07:35

Columns Today's Pre-Market Movers and Top Ratings | NVDA, KEYS, TGT, JPM and More

Morning Movers
Gapping up
$Comcast (CMCSA.US)$ stock increased by 2.5% following a report by the WSJ that the media giant was nearing approval for a $7 billion spinoff of its cable TV assets.
$NVIDIA (NVDA.US)$ stock went up by 0.44%, building on the near 5% gains from the previous session as the market anticipates its upcoming quarterly earnings report.
$Keysight Technologies (KEYS.US)$ stock jumped 9.4% after the company rel...

Nvidia's stock hit a new high after Q3 earnings!

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...